Rainmed Medical Limited (HK:2297)
:2297
Want to see HK:2297 full AI Analyst Report?
Top Page
Rainmed Medical Limited
(2297)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.26
▲(0.77% Upside)
Action:Reiterated
Date:06/13/26
The score is held back primarily by weak financial performance (shrinking revenue, negative gross margin, and persistent cash burn), with only partial support from a relatively low-leverage balance sheet. Technicals are modestly constructive in the near term but not strong enough to offset the fundamental risks, and valuation provides limited support given the ongoing losses and no dividend yield.
Positive Factors
Conservative capital structure
Low debt and a sizable equity base give Rainmed financial flexibility to weather continued operational losses and delay urgent refinancing. Over a 2–6 month horizon this reduces insolvency risk and preserves optionality to fund restructuring, R&D, or targeted commercialization efforts without immediate liquidity stress.
Negative Factors
Sharp revenue contraction
Steep multi-year revenue declines indicate lost market share or failing demand for current offerings, eroding scale and weakening operating leverage. Without revenue stabilization or new growth drivers, margin recovery and improved cash generation become much harder, prolonging dependence on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative capital structure
Low debt and a sizable equity base give Rainmed financial flexibility to weather continued operational losses and delay urgent refinancing. Over a 2–6 month horizon this reduces insolvency risk and preserves optionality to fund restructuring, R&D, or targeted commercialization efforts without immediate liquidity stress.
Read all positive factors
Rainmed Medical Limited (2297) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$364.35M
Dividend YieldN/A
Average Volume (3M)3.71M
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth-51.87%
EPS Growth38.90%
CountryHK
Employees270
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,401,358,800
10 Day Avg. Volume1,490,900
30 Day Avg. Volume3,709,666
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.88
Price to Sales (P/S)16.34
P/FCF Ratio-3.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rainmed Medical Limited Business Overview & Revenue Model
Company Description
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistan...
How the Company Makes Money
null...
Rainmed Medical Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.18M | 39.82M | 73.22M | 83.60M | 81.20M |
| Gross Profit | 9.04M | 23.87M | 48.55M | 69.82M | 69.03M |
| EBITDA | -67.39M | -82.98M | -93.54M | -1.33B | -623.97M |
| Net Income | -77.08M | -113.50M | -115.83M | -1.35B | -633.64M |
Balance Sheet | |||||
| Total Assets | 545.73M | 463.06M | 573.31M | 690.33M | 640.19M |
| Cash, Cash Equivalents and Short-Term Investments | 153.35M | 205.55M | 335.28M | 578.96M | 559.14M |
| Total Debt | 24.83M | 25.58M | 20.00M | 28.98M | 1.38B |
| Total Liabilities | 187.59M | 53.15M | 53.30M | 71.69M | 1.41B |
| Stockholders Equity | 357.54M | 407.00M | 515.05M | 618.64M | -774.48M |
Cash Flow | |||||
| Free Cash Flow | -79.69M | -138.10M | -235.27M | -141.04M | -103.95M |
| Operating Cash Flow | -76.40M | -84.31M | -124.29M | -111.22M | -72.83M |
| Investing Cash Flow | 7.24M | 6.31M | 180.29M | -515.74M | -27.98M |
| Financing Cash Flow | 30.15M | 723.00K | -15.88M | 120.73M | 633.85M |
Rainmed Medical Limited Technical Analysis
Positive
0.26
Price Trends
0.24
Positive
0.26
Negative
0.28
Negative
Market Momentum
<0.01
Negative
61.24
Neutral
69.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2297, the sentiment is Positive. The current price of 0.26 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.24, and below the 200-day MA of 0.28, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.24 is Neutral, neither overbought nor oversold. The STOCH value of 69.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2297.
Rainmed Medical Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$514.47M | 4.83 | 16.21% | 4.94% | 16.46% | 50.51% | |
59 Neutral | HK$2.71B | 19.12 | 7.22% | ― | 20.65% | 127.07% | |
59 Neutral | HK$3.08B | 58.34 | 2.07% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$364.35M | -4.09 | -20.20% | ― | -51.87% | 38.90% | |
43 Neutral | HK$359.54M | -2.34 | -11.54% | ― | -30.60% | 28.61% | |
42 Neutral | HK$582.14M | -1.22 | -21.29% | ― | -34.96% | 42.74% |
* Healthcare Sector Average
HK:2297
Rainmed Medical Limited
0.26
0.04
18.72%
HK:6669
Acotec Scientific Holdings Limited
8.64
1.04
13.68%
HK:1612
Vincent Medical Holdings Limited
0.78
0.33
74.89%
HK:2216
Broncus Holding Corp.
0.68
-1.36
-66.67%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.31
1.31
21.83%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.32
-1.20
-47.62%
Rainmed Medical Limited Corporate Events
Rainmed Medical Reshuffles Joint Company Secretary and Compliance Representative
Jun 8, 2026
Rainmed Medical Limited announced a change in its senior corporate governance roles, with joint company secretary and authorised representative Ms. Chu Cheuk Ting resigning effective June 8, 2026, citing other work arrangements and confirming no d...
Rainmed Medical Executive Director and Joint CEO Zhu Zeke Resigns Ahead of AGM
Jun 1, 2026
Rainmed Medical Limited announced that executive director and joint chief executive officer Zhu Zeke has resigned, effective June 1, 2026, citing a need to focus on family matters. The board stated that Zhu has no disagreement with directors or is...
Rainmed Medical Sets Out Board and Committee Structure
Jun 1, 2026
Rainmed Medical Limited has announced the current composition of its board of directors, led by executive chairman Huo Yunfei and supported by executive director Duan Jing, three non-executive directors and three independent non-executive director...
Rainmed Medical Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate
Apr 28, 2026
Rainmed Medical Limited has called its annual general meeting for June 29, 2026, in Suzhou, where shareholders will review and adopt the audited consolidated financial statements for the year ended December 31, 2025, and receive reports from the b...
Rainmed Medical Narrows Loss Amid Sharp Revenue Decline in 2025
Mar 31, 2026
Rainmed Medical reported a sharp deterioration in top-line performance for 2025, with revenue halving to RMB19.2 million and gross profit dropping 62.3%, pushing gross margin down to 46.9%. The company attributed the year’s loss mainly to co...
Rainmed Medical Sets Board Meeting to Approve 2025 Annual Results and Consider Dividend
Mar 17, 2026
Rainmed Medical Limited has scheduled a board meeting for March 31, 2026, to review and approve its annual results for the year ended December 31, 2025, and to authorize their publication. The board will also consider whether to recommend a final ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.